199 related articles for article (PubMed ID: 9824113)
1. p53 gene mutations in osteosarcomas of low-grade malignancy.
Radig K; Schneider-Stock R; Haeckel C; Neumann W; Roessner A
Hum Pathol; 1998 Nov; 29(11):1310-6. PubMed ID: 9824113
[TBL] [Abstract][Full Text] [Related]
2. Mutation spectrum of p53 gene in highly malignant human osteosarcomas.
Radig K; Schneider-Stock R; Oda Y; Neumann W; Mittler U; Roessner A
Gen Diagn Pathol; 1996 Jun; 142(1):25-32. PubMed ID: 8793483
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors.
Yokoyama R; Schneider-Stock R; Radig K; Wex T; Roessner A
Pathol Res Pract; 1998; 194(9):615-21. PubMed ID: 9793960
[TBL] [Abstract][Full Text] [Related]
5. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma.
Gokgoz N; Wunder JS; Mousses S; Eskandarian S; Bell RS; Andrulis IL
Cancer; 2001 Oct; 92(8):2181-9. PubMed ID: 11596036
[TBL] [Abstract][Full Text] [Related]
6. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog.
Johnson AS; Couto CG; Weghorst CM
Carcinogenesis; 1998 Jan; 19(1):213-7. PubMed ID: 9472714
[TBL] [Abstract][Full Text] [Related]
7. P53 gene mutations in osteosarcomas in the dog.
van Leeuwen IS; Cornelisse CJ; Misdorp W; Goedegebuure SA; Kirpensteijn J; Rutteman GR
Cancer Lett; 1997 Jan; 111(1-2):173-8. PubMed ID: 9022143
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
9. How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone?
Taubert H; Berger D; Hinze R; Meye A; Würl P; Hogendoorn PC; Holzhausen HJ; Schmidt H; Rath FW
Cancer Lett; 1998 Jan; 123(2):147-51. PubMed ID: 9489481
[TBL] [Abstract][Full Text] [Related]
10. p53 and ras mutations in Ewing's sarcoma.
Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A
Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933
[TBL] [Abstract][Full Text] [Related]
11. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
[TBL] [Abstract][Full Text] [Related]
12. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
13. Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma: a comparative study based on clinical, histological, and biological parameters.
Oliveira CR; Mendonça BB; Camargo OP; Pinto EM; Nascimento SA; Latorre Mdo R; Zerbini MC
Clinics (Sao Paulo); 2007 Apr; 62(2):167-74. PubMed ID: 17505702
[TBL] [Abstract][Full Text] [Related]
14. GNAS mutations are not detected in parosteal and low-grade central osteosarcomas.
Salinas-Souza C; De Andrea C; Bihl M; Kovac M; Pillay N; Forshew T; Gutteridge A; Ye H; Amary MF; Tirabosco R; Toledo SR; Baumhoer D; Flanagan AM
Mod Pathol; 2015 Oct; 28(10):1336-42. PubMed ID: 26248895
[TBL] [Abstract][Full Text] [Related]
15. Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma.
Grote HJ; Schneider-Stock R; Neumann W; Roessner A
Virchows Arch; 2000 May; 436(5):494-7. PubMed ID: 10881744
[TBL] [Abstract][Full Text] [Related]
16. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone.
Ueda Y; Dockhorn-Dworniczak B; Blasius S; Mellin W; Wuisman P; Böcker W; Roessner A
J Cancer Res Clin Oncol; 1993; 119(3):172-8. PubMed ID: 8418091
[TBL] [Abstract][Full Text] [Related]
17. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
[TBL] [Abstract][Full Text] [Related]
18. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP
J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571
[TBL] [Abstract][Full Text] [Related]
19. [Cytogenetic changes in low grade central osteosarcomas].
Werner M; Rieck J; Delling G
Verh Dtsch Ges Pathol; 1998; 82():189-94. PubMed ID: 10095432
[TBL] [Abstract][Full Text] [Related]
20. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
